Itraconazol Aristo

Itraconazole, the active ingredient in Itraconazol Aristo, is a triazole azole antifungal presented as an oral formulation for systemic use. Approved in the European Union, it treats a range of invasive and superficial fungal infections in adults and children when prescribed by a qualified healthcare professional.

GNH USA supplies Itraconazol Aristo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Itraconazole is employed to treat systemic and localized fungal infections across several disease categories.

Blastomycosis: clears pulmonary and disseminated infection. Histoplasmosis: resolves respiratory and disseminated disease. Aspergillosis: treats invasive pulmonary forms. Candidiasis (oropharyngeal and esophageal): eradicates mucosal infection. Dermatophyte infections: eliminates skin and nail fungal disease. Sporotrichosis: cures cutaneous and disseminated infection.

Itraconazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting. - Abdominal discomfort or pain. - Headache. - Rash or mild skin irritation. - Altered taste sensation. - Diarrhea.

Serious or Rare Side Effects: - Hepatotoxicity, including severe liver injury. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Congestive heart failure exacerbation. - Visual disturbances such as blurred vision. - Anaphylactic reactions. - Severe electrolyte abnormalities.

Before initiating therapy, clinicians should consider several safety measures.

Liver function monitoring: assess hepatic enzymes before and during treatment. Drug interaction review: evaluate concomitant CYP3A4 substrates and inhibitors. Cardiac risk assessment: avoid use in patients with uncontrolled congestive heart failure. Pregnancy and lactation: prescribe only when benefits outweigh potential risks. Store below 25°C: keep in the original container, protect from moisture.

Itraconazole interacts with many medicines; careful assessment is required.

Major Interactions (Avoid): - Rifampin: strong inducer that markedly reduces itraconazole exposure. - Ketoconazole: additive hepatotoxic potential. - St. John’s wort: potent CYP3A4 inducer, lowering efficacy. - Other azole‑resistant antifungals: may compromise therapeutic outcome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may increase itraconazole levels. - Statins (e.g., simvastatin, lovastatin): heightened risk of myopathy. - Oral anticoagulants (warfarin): potential increase in INR. - Oral hypoglycemics: possible alteration of blood glucose control.